ClinicalTrialsFinder
RecruitingPhase 2NCT05478083

A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease

Sponsor

University Medical Center Groningen

Enrollment

36 participants

Start Date

Jun 1, 2022

Study Type

INTERVENTIONAL

Conditions

Autosomal Dominant Polycystic KidneyPolycystic Liver Disease

Summary

Multicenter trial on the effect of the GnRH analogue leuprorelin on the growth of total liver volume in pre-menopausal women with very severe polycystic liver disease who, despite available therapy, experience growth and are heading for liver transplantation.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 45 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Leuprorelin for people with autosomal dominant polycystic kidney and polycystic liver disease. The study is currently recruiting participants at 2 locations. People eligible for this study include women aged 18 Years to 45 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLeuprorelin

Treatment consist of leuprorelin 3.75 mg once monthly for the first 3 months followed by 3-monthly injections of 11.25 mg. The direct start group will use leuprorelin for 36 months. The delayed start group will use standard of care in the first 18 months.

Locations(2)

Radboudumc

Nijmegen, Gelderland, Netherlands

Groningen universitair medical center

Groningen, Netherlands

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05478083

Related Trials

Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases

NCT059967311 location

A Prospective Observational Study of Foam Sclerotherapy .

NCT041116921 location

Polycystic Liver Disease Registry (UK)

NCT046452512 locations

Glucagon-Like Peptide-1 Receptor Agonist in ADPKD

NCT065828751 location

Analysis of Patients With Autosomal Dominant Polycystic Kidney

NCT067591421 location